These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37714742)

  • 21. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study.
    Rodriguez-Vida A; Valderrama BP; Castellano D; Pinto A; Mellado B; Puente J; Climent MA; Domenech M; Vazquez F; Perez-Gracia JL; Bonfill T; Morales-Barrera R; Gonzalez-Billalabeitia E; Garcia-Del-Muro X; Maroto P; Navarro-Gorro N; Juanpere N; Juan O; Bellmunt J
    ESMO Open; 2024 Sep; 9(9):103690. PubMed ID: 39214051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland.
    Critchlow S; Bullement A; Crabb S; Jones R; Christoforou K; Amin A; Xiao Y; Kapetanakis V; Benedict Á; Chang J; Kearney M; Eccleston A
    Future Oncol; 2024 Mar; 20(8):459-470. PubMed ID: 37529943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A cost-effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan.
    Su PJ; Xiao Y; Lin AY; Goh C; Wu E; Liu K; Chou P; Kuo K; Palencia R; Chang J; Kearney M; Kapetanakis V; Benedict A
    Cancer Rep (Hoboken); 2023 Oct; 6(10):e1887. PubMed ID: 37640556
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma.
    Bellmunt Molins J; García-Donas Jiménez J; Valderrama BP; Virizuela Echaburu JA; Hernando-Polo S; Climent Durán MÁ; Villa-Guzmán JC; Arranz Arija JÁ; Ostiategui ML; Milagro NL; González-Del-Alba A; González BM; Díaz EG; Gauna DC; Santasusana MD; Herranz UA; Del Muro Solans XG; Pérez-Gracia JL; Vázquez JP; Morales-Barrera R; Pous AF
    Clin Genitourin Cancer; 2020 Dec; 18(6):452-460. PubMed ID: 32565133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.
    Bakaloudi DR; Talukder R; Lin GI; Makrakis D; Diamantopoulos LN; Tripathi N; Agarwal N; Zakopoulou R; Bamias A; Brown JR; Pinato DJ; Korolewicz J; Jindal T; Koshkin VS; Murgić J; Miletić M; Frobe A; Johnson J; Zakharia Y; Drakaki A; Rodriguez-Vida A; Rey-Cárdenas M; Castellano D; Buznego LA; Duran I; Carballeira CC; Barrera RM; Marmorejo D; McKay RR; Stewart T; Gupta S; Ruplin AT; Yu EY; Khaki AR; Grivas P
    Clin Genitourin Cancer; 2023 Oct; 21(5):584-593. PubMed ID: 37414620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma.
    Xie Q; Zheng H; Chen Y; Peng X
    Front Public Health; 2022; 10():837854. PubMed ID: 35570929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-World Evidence of Tumor and Patient Characteristics and Survival with Avelumab Maintenance after Chemotherapy for Advanced and Metastatic Urothelial Carcinoma.
    Banek S; Wenzel M; Lauer B; Le QC; Hoeh B; Koll F; Cano Garcia C; Humke C; Köllermann J; Chun FKH; Kosiba M; Kluth LA
    Urol Int; 2024; 108(4):285-291. PubMed ID: 38447555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial.
    Reck M; Barlesi F; Yang JC; Westeel V; Felip E; Özgüroğlu M; Dols MC; Sullivan R; Kowalski DM; Andric Z; Lee DH; Sezer A; Hu P; Wang X; von Heydebreck A; Jacob N; Mehr KT; Park K
    J Thorac Oncol; 2024 Feb; 19(2):297-313. PubMed ID: 37748693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific region.
    Eto M; Lee JL; Chang YH; Gao S; Singh M; Gurney H
    Asia Pac J Clin Oncol; 2022 Oct; 18(5):e191-e203. PubMed ID: 35238147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma.
    Lapuente M; Conway D; Wood LS; Kehoe K; Carroll Bullock A; Devgan G; Burns KD
    Clin J Oncol Nurs; 2023 Jan; 27(1):71-80. PubMed ID: 37677821
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating Real-World Characteristics of Patients With Advanced Urothelial Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective Medical Chart Review.
    Bellmunt J; Chang J; Pavilack-Kirker M; Cappelleri JC; Costa N; Esterberg E; Kearney M; Hitchens A; Candrilli SD; Ajmera M
    Clin Genitourin Cancer; 2023 Aug; 21(4):459-466. PubMed ID: 37149458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
    Mansinho A; Cruz A; Marconi L; Pinto C; Augusto I
    Adv Ther; 2023 Oct; 40(10):4134-4150. PubMed ID: 37608243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
    Monk BJ; Colombo N; Oza AM; Fujiwara K; Birrer MJ; Randall L; Poddubskaya EV; Scambia G; Shparyk YV; Lim MC; Bhoola SM; Sohn J; Yonemori K; Stewart RA; Zhang X; Perkins Smith J; Linn C; Ledermann JA
    Lancet Oncol; 2021 Sep; 22(9):1275-1289. PubMed ID: 34363762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab
    Minato A; Furubayashi N; Tomoda T; Masaoka H; Song Y; Hori Y; Kiyoshima K; Negishi T; Kuroiwa K; Seki N; Tomisaki I; Nakamura M; Harada K; Fujimoto N
    Anticancer Res; 2024 Aug; 44(8):3419-3426. PubMed ID: 39060065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy.
    Bellmunt J; Fougeray R; Rosenberg JE; von der Maase H; Schutz FA; Salhi Y; Culine S; Choueiri TK
    Ann Oncol; 2013 Jun; 24(6):1466-72. PubMed ID: 23419284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
    Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
    Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.
    Tural D; Ölmez ÖF; Sümbül AT; Artaç M; Özhan N; Akar E; Çakar B; Köstek O; Ekenel M; Erman M; Coşkun HŞ; Selçukbiricik F; Keskin Ö; Türköz FP; Oruç K; Bayram S; Yılmaz U; Bilgetekin İ; Yıldız B; Şendur MAN; Paksoy N; Dirican A; Erdem D; Selam M; Tanrıverdi Ö; Paydaş S; Urakçı Z; Atağ E; Güncan S; Ürün Y; Alkan A; Kaya AO; Özyükseler DT; Taşkaynatan H; Yıldırım M; Sönmez M; Başoğlu T; Gündüz Ş; Kılıçkap S
    Eur Urol Focus; 2021 Sep; 7(5):1061-1066. PubMed ID: 33008789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
    Matsubara N; de Wit R; Balar AV; Siefker-Radtke AO; Zolnierek J; Csoszi T; Shin SJ; Park SH; Atduev V; Gumus M; Su YL; Karaca SB; Cutuli HJ; Sendur MAN; Shen L; O'Hara K; Okpara CE; Franco S; Moreno BH; Grivas P; Loriot Y
    Eur Urol; 2024 Mar; 85(3):229-238. PubMed ID: 37778952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.
    Bang YJ; Ruiz EY; Van Cutsem E; Lee KW; Wyrwicz L; Schenker M; Alsina M; Ryu MH; Chung HC; Evesque L; Al-Batran SE; Park SH; Lichinitser M; Boku N; Moehler MH; Hong J; Xiong H; Hallwachs R; Conti I; Taieb J
    Ann Oncol; 2018 Oct; 29(10):2052-2060. PubMed ID: 30052729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve.
    Gross-Goupil M; Domblides C; Lefort F; Ravaud A
    Bull Cancer; 2020 Jun; 107(5S):eS1-eS7. PubMed ID: 32620210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.